NEW YORK (GenomeWeb News) – Lab21 today announced an agreement with IntegraGen to develop a microRNA-based assay to identify colorectal cancer patients who may best respond to EGFR-inhibitor therapy.

Lab21 will develop an assay based on its SPARQ PCR technology to detect the expression levels of a miRNA biomarker called hsa-mir-31-3p. IntegraGen and its academic partners discovered and patented the biomarker, which has shown an ability to predict EGFR-inhibitor response in KRAS wild-type patients with metastatic colorectal cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.